US20120071557A1 - Animal feed compositions of abscisic acid - Google Patents

Animal feed compositions of abscisic acid Download PDF

Info

Publication number
US20120071557A1
US20120071557A1 US13/236,472 US201113236472A US2012071557A1 US 20120071557 A1 US20120071557 A1 US 20120071557A1 US 201113236472 A US201113236472 A US 201113236472A US 2012071557 A1 US2012071557 A1 US 2012071557A1
Authority
US
United States
Prior art keywords
aba
feed
livestock
fish
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/236,472
Inventor
Maria Pilar Herrero
Warren E. Shafer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valent BioSciences LLC
Original Assignee
Valent BioSciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valent BioSciences LLC filed Critical Valent BioSciences LLC
Priority to US13/236,472 priority Critical patent/US20120071557A1/en
Assigned to VALENT BIOSCIENCES CORPORATION reassignment VALENT BIOSCIENCES CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HERRERO, MARIA PILAR, SHAFER, WARREN E.
Publication of US20120071557A1 publication Critical patent/US20120071557A1/en
Priority to US14/717,110 priority patent/US20150250209A1/en
Priority to US16/593,677 priority patent/US20200030269A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/105Aliphatic or alicyclic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/30Feeding-stuffs specially adapted for particular animals for swines
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/50Feeding-stuffs specially adapted for particular animals for rodents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/70Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75Feeding-stuffs specially adapted for particular animals for birds for poultry
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/80Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention generally relates to compositions comprising abscisic acid, and/or salts, and derivatives thereof, and methods of their preparation and administration for uses with livestock and in aquaculture.
  • Abscisic acid is a naturally occurring plant hormone that is well known to be involved in plant response to stress. The chemistry and physiology of abscisic acid and its analogs is described by Milborrow, Ann. Rev. Plant Physiol. 1974, 25, 259-307. The naturally occurring enantiomeric form of abscisic acid is (S)-(+)-abscisic acid. The stereochemistry of the side chain of the major part of naturally occurring abscisic acid is 2-cis-,4-trans-, since that is the isomer that is produced biosynthetically by all green plants and some microorganisms.
  • Abscisic acid is a carboxylic acid, and thus in a medium having an acidic pH, it is protonated in its neutral undissociated form. This uncharged, undissociated form is more lipophilic than a salt of abscisic acid is in its dissociated form of abscisic acid that is present at higher pH (Blumenfeld and Bukovac 1972, Planta 107: 261-268).
  • abscisic acid is used in agriculture and horticulture on or around crops and plants for various purposes, such as improving stress tolerance, slowing the growth rate, adjusting flowering phase, and other purposes. Abscisic acid has also been reported to possess insect inhibition qualities. See U.S. Pat. Nos. 4,434,180 and 4,209,530. Others have reported potential medicinal properties of abscisic acid, for example U.S. Patent Application No. 2006/0292215 discloses methods of using abscisic acid for anti-cancer purposes, and International Application No. WO 2007/042983 discloses anti-inflammatory activity of abscisic acid. All toxicology studies conducted to this point indicate abscisic acid, is a safe, nontoxic substance.
  • abscisic acid, and/or salts, derivatives and analogs thereof have health and feed benefits for livestock and aquaculture.
  • the present invention is generally directed to compositions comprising abscisic acid, and/or salts, and derivatives thereof (collectively referred to as “ABA” herein), of which (S)-(+)-abscisic acid is one enantiomer (hereinafter referred to as “S-ABA”), and methods of their use to maintain the health of livestock and fish comprising administering to livestock or fish a effective amount of ABA.
  • ABA abscisic acid, and/or salts, and derivatives thereof
  • the present invention is also directed to methods of increasing feed efficiency comprising administering to livestock or fish an effective amount of ABA.
  • Another embodiment of the present invention is directed to methods of increasing weight gain of livestock and fish comprising administering to an animal an effective amount of ABA.
  • Another embodiment of the present invention is directed to methods of decreasing the time to market of livestock and fish comprising administering to livestock or fish an effective amount of ABA.
  • a different embodiment of the present invention is directed to methods of increasing the meat quantity of livestock and fish comprising administering to livestock or fish an effective amount of ABA.
  • the present invention is directed to methods of increasing immunological function comprising administering to livestock or fish in need thereof an effective amount of ABA. This effect is supported by an increase in digestive tract weight, suggesting better overall animal health.
  • the present invention is directed to methods for reducing or eliminating the use of antibiotics in feed comprising administering to an livestock or fish an effective amount of ABA.
  • compositions of the present invention generally comprise ABA.
  • Other components which enhance the biological activity of the ABA may optionally be included.
  • the present invention is specifically directed to compositions comprising ABA, of which (S)-(+)-abscisic acid is one enantiomer, and methods of their use to treat various animal ailments, as well be used as feed for animals and animal breeders.
  • ABS-ABA is the preferred compound of the compositions and uses herein and has the structure as follows:
  • compositions and methods of the inventions encompass all isomeric forms of the described abscisic acids, their racemic mixtures, enol forms, solvated and unsolvated forms, analogs, prodrugs, derivatives, including but not limited to esters and ethers, and pharmaceutically acceptable salts
  • suitable salts include inorganic salts such as the ammonium, lithium, sodium, potassium, magnesium, and potassium salts and organic amine salts such as the triethanolamine, dimethanolamine and ethanolamine salts.
  • the organic amine salt is the triethanolamine salt.
  • the organic amine salt is the dimethylethanolamine salt.
  • the organic amine salt is the ethanolamine salt.
  • salts are not limiting as other salts may also be suitable for use in the present invention.
  • One presently preferred salt is the ammonium salt.
  • Other preferred salts are the sodium and potassium salts.
  • the salts may be prepared by contacting the acid form with a sufficient amount of the desired base to produce a salt in the conventional manner.
  • the free acid forms may be regenerated by treating the salt with a suitable dilute aqueous acid solution such as dilute aqueous sulfuric, hydrochloric or phosphoric acid.
  • the free acid forms differ from their respective salt forms somewhat in certain physical properties, such as their solubilities in polar solvents, but the salts are equivalent to their respective free acid forms for purposes of the invention. (See, for example S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 66: 1-19 (1977) which is incorporated herein by reference).
  • livestock and fish refer to any livestock or fish, or offspring of livestock or fish, who is receiving treatment, is in need of treatment, is taking or receiving treatment for prevention purposes, and/or is being administered the composition.
  • offspring refers to progeny or descendants of livestock or fish, and includes born progeny, fetuses and embryos.
  • Livestock shall include poultry, including chickens, which includes boilers and layers and male and female breeding stock, geese, duck, turkey, pheasant, cornish hens, swine, cattle, which includes beef and dairy production, sheep, and goats.
  • “Fish” shall include catfish, carp, tilapia, trout, crayfish, shrimp, lobster, crab, aquatic mammals, salmon, and white fish.
  • administering includes any means for introducing the ABA of the invention and other therapeutic agents, into the body, preferably into the systemic circulation.
  • examples include but are not limited to oral, including feed and/or drinking water, buccal, sublingual, pulmonary, ophthalmic, transdermal, transmucosal, as well as subcutaneous, intraperitoneal, intravenous, intramuscular injection, transplacental transfer and lactation.
  • treating and “treatment” have a commonly understood meaning of administration of a remedy to livestock or fish, or the parent of livestock or fish, who has or is suspected of having a disease or a condition, and refer to reversing, alleviating, inhibiting, or slowing the progress of the disease, disorder, or condition to which such terms apply, or one or more symptoms of such disease, disorder, or condition, or preventing or decreasing the chances of a disease, condition, disorder or outcome from occurring, or to increase effects of a specified physiological response or health benefit.
  • preventing and prevention refer to prophylactic use to reduce the likelihood of a disease, disorder, or condition to which such term applies, or one or more symptoms of such disease, disorder, or condition. It is not necessary to achieve a 100% likelihood of prevention; it is sufficient to achieve at least a partial effect of reducing the risk of acquiring such disease, disorder, or condition.
  • composition includes a product comprising ABA (and in the specified amounts, if indicated), including products with exogenous or up-regulated ABA, as well as any product which results, directly or indirectly, from combination of ABA with specified ingredients in the specified amounts.
  • the term “effective amount” means an amount of a compound that, when administered to livestock or fish for treating a disease, condition or attaining a desired result, is sufficient to effect such treatment for the disease or desired result.
  • the “effective amount” will vary depending on the compound, the disease state being treated or health benefit desired, the severity or the disease treated, the result desired, the age and relative health of the livestock or fish, the route and form of administration, the judgment of the attending medical or veterinary practitioner, breeder, trainer, or person attending or caring for the livestock or fish, and other factors.
  • the amount of ABA that is “effective” will vary from composition to composition, depending on the particular use, the particular ABA, salts, derivatives and analogs thereof, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective amount” in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • Method of Ton refers to 2,205 pounds or 1,000 kg.
  • Ton also known as a “short ton”, refers to 2,000 pounds or 907 kg.
  • compositions of the present invention may be incorporated with compound feed, or commercial pelleted food produced in a feed mill and fed to domestic livestock and fish.
  • the compositions of the present invention may be incorporated with fodder, or food given to domestic livestock including plants cut and carried to them.
  • the compositions of the present invention may be incorporated with forage, or growing plants eaten by domestic livestock. It is within a skill in the art to formulate the compositions with foodstuffs for oral consumption.
  • compositions of the present invention may be formulated in a liquid composition for oral consumption. It is within a skill in the art to formulate the compositions in liquid compositions for oral consumption.
  • compositions of the present invention may be added to water used for livestock or fish production.
  • composition of the present invention is added to an aquaculture system used to grow fish, aquatic mammals, or crustaceans.
  • An embodiment of the present invention is directed to methods of reducing mortality of livestock and fish comprising administering to livestock or fish an effective amount of ABA.
  • Another varying embodiment of the present invention is directed to methods of increasing weight gain of livestock and fish comprising administering to livestock and fish an effective amount of ABA.
  • Another embodiment of the present invention is directed to methods of decreasing the time to market of livestock and fish comprising administering to livestock and fish an effective amount of ABA. It is also contemplated that a different embodiment of the present invention is directed to methods of increasing the meat quantity of livestock and fish comprising administering to livestock and fish an effective amount of ABA.
  • An embodiment of the present invention is directed to methods of increasing immunological function in livestock and fish comprising administering to livestock or fish in need thereof an effective amount of ABA.
  • a preferred range of an effective amount of ABA for the various methods is from about 1 gram/MT of feed to about 2000 grams/MT of feed.
  • a more preferred range of ABA is from about 5 grams/MT of feed to about 500 grams/MT of feed.
  • a person having ordinary skill in the art would be able to adjust these ranges for various uses like aquaculture applications without undue experimentation.
  • Animal feed for feeding poultry includes protein, fat, fiber, calcium, and phosphorous.
  • a preferred feed would include corn and/or wheat, soybean meal, fat, animal by-product, meat and bone meal, and vitamins and minerals.
  • premix When used in poultry feed, ABA can be initially mixed into a premix.
  • premix is intended to mean a feed composition that is prepared as an initial mix containing the active ingredient and, for example, a carrier, and is then blended into the final feed.
  • the premix is blended with about one metric ton (MT) of conventional feed, with the result that the necessary dosage requirements of the ABA are provided to the animals.
  • MT metric ton
  • the premix of the invention preferably comprises about 1 to 2000, and more preferably, about 5 to 500, grams of ABA.
  • Carriers for use in a premix are well known by those having skill in the art, and appropriate concentrations can be readily determined.
  • the ABA may be added to the carrier as a dry powder or as a liquid solution or suspension.
  • the ABA When added as a liquid, the ABA may be dissolved or suspended in a liquid with stirring at room temperature.
  • a liquid may be water or a suitable solvent or another product used for animal feed that is already in liquid form. Because of ABA's liquid solubility characteristics, it may form a suspension.
  • a predetermined amount of ABA is then added to the conventional premix, and will not overly wet it. Once the premix is prepared, the premix is then added to the final feed, preferably at a rate in the range of one quarter of a pound (lb.) to five pounds (lbs.) of premix to one metric ton (MT) of feed, to supply daily requirements of the ABA for the poultry.
  • the ABA solid or solution or liquid suspension can be added directly to the premix material, and then mixed.
  • Mixing can be accomplished by any known means, such as by a standard horizontal or vertical blender. Mixing time will again vary depending upon the particular ingredients of the premix, and can take as long as is necessary to assure that the ingredients are thoroughly mixed.
  • the premix is then incorporated into the feed to be fed to the poultry.
  • ABA is blended with the carrier to form the premix, and the premix is directly blended into the final feed. While there is no evidence that use of the higher amounts would cause any toxicity problems in treated poultry, it will affect cost considerations. Because the premix generally will be added to one-ton charges of feed (as is common in the industry), the correspondence between one gram of ABA added to the premix yields about 1 ppm concentration of ABA in the feed. Thus, 5 grams of ABA added to one pound of premix, which in turn is added to one metric ton (MT) of feed, yields about a 5 ppm effective ABA concentration.
  • MT metric ton
  • ABA can be mixed with a premix material prior to incorporation into the finished feed
  • the appropriate amount of ABA may be directly blended into or sprayed upon the feed.
  • the preferred additive range of ABA in finished feed, whether added directly or via a premix, is about 1 to 2000 grams per metric ton (MT) of feed; more preferably about 5 to 500 grams per metric ton (MT) of feed.
  • Feed is conventionally prepared in a large bin or mixer in which the feed ingredients are added in descending weight order according to their prevalence in the ultimate feed mixture. Thus, cracked or ground grain would be the primary ingredient. Minor ingredients are then added. Micro-ingredients are added last. These include vitamins, drugs, growth promoters, antibiotics, and, in the present case, ABA. Thus, ABA can be one of the micro-ingredients and is added to the feed in the final blending step. The feed is blended for conventional time periods.
  • the feed comprising the ABA is fed to livestock and fish in standard form, such as a mash, crumble or pellet, and at standard feed dosage ranges and rates.
  • Another embodiment of the present invention is liquid compositions that can be prepared as either ready-to-use dilutions or dilutable concentrates.
  • the embodiment of the present invention can be a solution containing from 0.5% to as much as 50% by weight of ABA.
  • the dilutable concentrates can be diluted into water directly to a final application concentration or to any intermediate dilution, without risk of precipitation of the active ingredient.
  • the aqueous formulations according to one embodiment of the present invention are inexpensive to manufacture, safe to handle and use, and the ABA active ingredient is stable under storage and shipping conditions.
  • a person having ordinary skill in the art would be able to determine how to prepare the final aqueous solution concentration for direct application to animals without undue experimentation, without any chance of causing precipitation of the active ingredient, and without long and laborious stirring to bring the active ingredient into solution.
  • Another embodiment of the present invention is an ABA water solution that serves as a drinking source of water for the livestock and fish.
  • Such supplemented water solution could be prepared by dissolving dry powder ABA in drinking water or by using a liquid solution or suspension concentrate of ABA.
  • the preferred additive range of ABA in drinking water is about 1 to 2000 parts per million (ppm) or about 1 to 2000 milligrams of ABA per liter of water; more preferably about 5 to 500 parts per million (ppm) or about 5 to 500 milligrams of ABA per liter of water.
  • a person having ordinary skill in the art would be able to determine how to prepare the final aqueous solution for direct application to livestock and fish without undue experimentation, without any chance of causing precipitation of the active ingredient, and without long and laborious stirring to bring the active ingredient into solution.
  • ABA can be applied directly onto animal feed once it has been prepared.
  • the ABA can be applied directly to the finished feed.
  • an aqueous solution of ABA is sprayed onto the finished feed in its final form, such as a pellet, prior to delivering the feed to the livestock and fish.
  • mice Male Cobb 500 chickens were fed different levels of S-ABA supplemented into starter, grower, and finisher feed diets for their entire 42 day commercial life cycle. On day 43, samples of chickens (sometimes referred to as “birds”) from each treatment were processed.
  • the starter, grower, and finisher basal diets represented standard commerical broiler diets.
  • the starter and grower diets contained Salinomycin (a coccidiostat) at 40 grams/ton.
  • the basal diets and final treatment diets were prepared using a 500 or 4,000 pound capacity vertical mixer or a 14,000 pound capacity horizontal mixer. After correcting for percent purity of S-ABA in the S-ABA dry powder, S-ABA was added to the basal diets at concentrations of 5, 50, or 500 ppm (4.6, 46, or 455 grams of S-ABA/ton).
  • Control treatments included (1) commercial diet only and (2) commercial diet supplemented with antibiotics (bacitracin methylene disalicylate (BMD), and STAFAC® virginiamycin (hereinafter “Stafac”). STAFAC is a registered trademark of Phibro Animal Health Corporation). All feed diets were pelleted at ⁇ 65° C. or below.
  • a 90-pen test facility was divided into 10 blocks containing 9 pens per block. Treatments were assigned to the pens using a complete randomized block design. Birds were assigned to the pens randomly. Specific treatment groups were as follows:
  • Birds were vaccinated for Mareks at the hatchery. Birds were vaccinated upon receipt for the study (day 0) for Newcastle and Infectious Bronchitis via spray cabinet. No other vaccinations or treatments, except what is provided in the diets were administered during the study.
  • Water was provided ad libitum throughout the study via one automatic four-nipple drinker in each pen. Drinkers were checked twice daily to assure a constant and clean water supply to the birds.
  • Feed was provided ad libitum throughout the study via one handing, ⁇ 17-inch diameter tube feeder per pen. Chick feeder trays were placed in each pen for approximately the first 4 days. Feed added and removed from pens was weighed and recorded from day 0 to day 42. Diet changes were conducted at the same time for all pens. The feeding period for each diet was as shown below:
  • Birds were weighed by pen at 0, 7, 14, 21, 28, 35, and 42 days of age. The feed remaining in each pen was weighed and recorded on study day 0, 7, 14, 21, 28, 35, and 42 days of age. The feed intake during days 0-7, 0-14, 0-21, 0-28, 0-35, and 0-42 was calculated.
  • Performance data was summarized by average weight per bird at each body weights measurement period.
  • the average feed conversion was calculated for each respective body weight period using the total feed consumption in a pen divided by the total weight of surviving birds (i.e. days 0-7, 0-14, 0-21, etc.). Adjusted feed conversion was calculated using the total feed consumption in a pen divided by the total weight of surviving birds and weight of birds that died or were removed from that pen.
  • TABLE 3 shows that S-ABA in the feed diet increases the weight of digestive tracts compared to the commercial feed diets (control 1 and control 2).
  • Increased digestive tract weights may be directly related to better overall health. Further, data in TABLE 3 suggest that S-ABA may also reduce or eliminate the need for antibiotics in feed.
  • TABLE 4 shows the economic benefit of improved health and growth of broiler chickens and increased feeding efficiency resulting from the addition of S-ABA into commercial feed.
  • the starter, grower, and finisher basal diets represented standard commercial broiler diets.
  • the starter and grower diets contained Salinomycin (a coccidiostat) at 40 grams/ton.
  • the basal diets and final treatment diets were prepared using a 500 or 4,000 pound capacity vertical mixer or a 14,000 pound capacity horizontal mixer. After correcting for percent purity of S-ABA in the S-ABA dry powder, S-ABA was added to the basal diets at concentrations of 2.5, 5.0, or 7.5 ppm (2.3, 4.6, or 6.8 grams of S-ABA/ton).
  • Control treatments included (1) commercial diet only and (2) commercial diet supplemented with antibiotics (bacitracin methylene disalicylate and Stafac). All feed diets were pelleted at ⁇ 65° C. or below.
  • a 108-pen test facility was divided into 18 blocks containing 6 pens per block. Treatments were assigned to the pens using a complete randomized block design. Birds were assigned to the pens randomly. Specific treatment groups were as follows:
  • Birds were vaccinated for Mareks at the hatchery. Birds were vaccinated upon receipt for the study (day 0) for Newcastle and Infectious Bronchitis via spray cabinet. No other vaccinations or treatments, except what is provided in the diets were administered during the study.
  • Water was provided ad libitum throughout the study via one automatic four-nipple drinker in each pen. Drinkers were checked twice daily to assure a constant and clean water supply to the birds.
  • Feed was provided ad libitum throughout the study via one handing, ⁇ 17-inch diameter tube feeder per pen. Chick feeder trays were placed in each pen for approximately the first 4 days. Feed added and removed from pens was weighed and recorded from day 0 to day 42. Diet changes were conducted at the same time for all pens. The feeding period for each diet was as shown below:
  • Birds were weighed by pen at 0, 7, 14, 21, 28, 35, and 42 days of age. The feed remaining in each pen was weighed and recorded on study day 0, 7, 14, 21, 28, 35, and 42 days of age. The feed intake during days 0-7, 0-14, 0-21, 0-28, 0-35, and 0-42 was calculated.
  • Performance data was summarized by average weight per bird at each body weights measurement period.
  • the average feed conversion was calculated for each respective body weight period using the total feed consumption in a pen divided by the total weight of surviving birds (i.e. days 0-7, 0-14, 0-21, etc.). Adjusted feed conversion was calculated using the total feed consumption in a pen divided by the total weight of surviving birds and weight of birds that died or were removed from that pen.

Abstract

The invention relates to compositions comprising abscisic acid, and/or salts, and derivatives thereof, and methods of using the same for improving the health, growth, and feed efficiency of livestock and fish as well as the quantity of meat produced in livestock in particular.

Description

    FIELD OF THE INVENTION
  • The present invention generally relates to compositions comprising abscisic acid, and/or salts, and derivatives thereof, and methods of their preparation and administration for uses with livestock and in aquaculture.
  • BACKGROUND OF THE INVENTION
  • Abscisic acid is a naturally occurring plant hormone that is well known to be involved in plant response to stress. The chemistry and physiology of abscisic acid and its analogs is described by Milborrow, Ann. Rev. Plant Physiol. 1974, 25, 259-307. The naturally occurring enantiomeric form of abscisic acid is (S)-(+)-abscisic acid. The stereochemistry of the side chain of the major part of naturally occurring abscisic acid is 2-cis-,4-trans-, since that is the isomer that is produced biosynthetically by all green plants and some microorganisms. Abscisic acid is a carboxylic acid, and thus in a medium having an acidic pH, it is protonated in its neutral undissociated form. This uncharged, undissociated form is more lipophilic than a salt of abscisic acid is in its dissociated form of abscisic acid that is present at higher pH (Blumenfeld and Bukovac 1972, Planta 107: 261-268).
  • Commercial formulations comprising abscisic acid are used in agriculture and horticulture on or around crops and plants for various purposes, such as improving stress tolerance, slowing the growth rate, adjusting flowering phase, and other purposes. Abscisic acid has also been reported to possess insect inhibition qualities. See U.S. Pat. Nos. 4,434,180 and 4,209,530. Others have reported potential medicinal properties of abscisic acid, for example U.S. Patent Application No. 2006/0292215 discloses methods of using abscisic acid for anti-cancer purposes, and International Application No. WO 2007/042983 discloses anti-inflammatory activity of abscisic acid. All toxicology studies conducted to this point indicate abscisic acid, is a safe, nontoxic substance.
  • Here, Applicants surprisingly discovered that abscisic acid, and/or salts, derivatives and analogs thereof, have health and feed benefits for livestock and aquaculture.
  • SUMMARY OF THE INVENTION
  • The present invention is generally directed to compositions comprising abscisic acid, and/or salts, and derivatives thereof (collectively referred to as “ABA” herein), of which (S)-(+)-abscisic acid is one enantiomer (hereinafter referred to as “S-ABA”), and methods of their use to maintain the health of livestock and fish comprising administering to livestock or fish a effective amount of ABA.
  • The present invention is also directed to methods of increasing feed efficiency comprising administering to livestock or fish an effective amount of ABA.
  • It is contemplated that another embodiment of the present invention is directed to methods of increasing weight gain of livestock and fish comprising administering to an animal an effective amount of ABA.
  • It is also contemplated that another embodiment of the present invention is directed to methods of decreasing the time to market of livestock and fish comprising administering to livestock or fish an effective amount of ABA.
  • It is also contemplated that a different embodiment of the present invention is directed to methods of increasing the meat quantity of livestock and fish comprising administering to livestock or fish an effective amount of ABA.
  • In another embodiment, the present invention is directed to methods of increasing immunological function comprising administering to livestock or fish in need thereof an effective amount of ABA. This effect is supported by an increase in digestive tract weight, suggesting better overall animal health.
  • In yet another embodiment, the present invention is directed to methods for reducing or eliminating the use of antibiotics in feed comprising administering to an livestock or fish an effective amount of ABA.
  • Compositions of the present invention generally comprise ABA. Other components which enhance the biological activity of the ABA may optionally be included.
  • The disclosed embodiments are simply exemplary embodiments of the inventive concepts disclosed herein and should not be considered as limiting, unless the claims expressly state otherwise.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is specifically directed to compositions comprising ABA, of which (S)-(+)-abscisic acid is one enantiomer, and methods of their use to treat various animal ailments, as well be used as feed for animals and animal breeders.
  • DEFINITIONS
  • The term “Abscisic acid” as used herein shall include salts and derivatives (collectively referred to as “ABA”). S-ABA is the preferred compound of the compositions and uses herein and has the structure as follows:
  • Figure US20120071557A1-20120322-C00001
  • Compositions and methods of the inventions encompass all isomeric forms of the described abscisic acids, their racemic mixtures, enol forms, solvated and unsolvated forms, analogs, prodrugs, derivatives, including but not limited to esters and ethers, and pharmaceutically acceptable salts, Examples of suitable salts that can be used include inorganic salts such as the ammonium, lithium, sodium, potassium, magnesium, and potassium salts and organic amine salts such as the triethanolamine, dimethanolamine and ethanolamine salts. In one embodiment, the organic amine salt is the triethanolamine salt. In another embodiment, the organic amine salt is the dimethylethanolamine salt. In yet another embodiment, the organic amine salt is the ethanolamine salt. These examples of salts are not limiting as other salts may also be suitable for use in the present invention. One presently preferred salt is the ammonium salt. Other preferred salts are the sodium and potassium salts. The salts may be prepared by contacting the acid form with a sufficient amount of the desired base to produce a salt in the conventional manner. The free acid forms may be regenerated by treating the salt with a suitable dilute aqueous acid solution such as dilute aqueous sulfuric, hydrochloric or phosphoric acid. The free acid forms differ from their respective salt forms somewhat in certain physical properties, such as their solubilities in polar solvents, but the salts are equivalent to their respective free acid forms for purposes of the invention. (See, for example S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 66: 1-19 (1977) which is incorporated herein by reference).
  • The term “livestock and fish” refer to any livestock or fish, or offspring of livestock or fish, who is receiving treatment, is in need of treatment, is taking or receiving treatment for prevention purposes, and/or is being administered the composition. The term “offspring” refers to progeny or descendants of livestock or fish, and includes born progeny, fetuses and embryos. “Livestock” shall include poultry, including chickens, which includes boilers and layers and male and female breeding stock, geese, duck, turkey, pheasant, cornish hens, swine, cattle, which includes beef and dairy production, sheep, and goats. “Fish” shall include catfish, carp, tilapia, trout, crayfish, shrimp, lobster, crab, aquatic mammals, salmon, and white fish.
  • The term “administering” or “administration” includes any means for introducing the ABA of the invention and other therapeutic agents, into the body, preferably into the systemic circulation. Examples include but are not limited to oral, including feed and/or drinking water, buccal, sublingual, pulmonary, ophthalmic, transdermal, transmucosal, as well as subcutaneous, intraperitoneal, intravenous, intramuscular injection, transplacental transfer and lactation.
  • The term “treating” and “treatment” have a commonly understood meaning of administration of a remedy to livestock or fish, or the parent of livestock or fish, who has or is suspected of having a disease or a condition, and refer to reversing, alleviating, inhibiting, or slowing the progress of the disease, disorder, or condition to which such terms apply, or one or more symptoms of such disease, disorder, or condition, or preventing or decreasing the chances of a disease, condition, disorder or outcome from occurring, or to increase effects of a specified physiological response or health benefit.
  • The terms “preventing” and “prevention” refer to prophylactic use to reduce the likelihood of a disease, disorder, or condition to which such term applies, or one or more symptoms of such disease, disorder, or condition. It is not necessary to achieve a 100% likelihood of prevention; it is sufficient to achieve at least a partial effect of reducing the risk of acquiring such disease, disorder, or condition.
  • The term “composition” includes a product comprising ABA (and in the specified amounts, if indicated), including products with exogenous or up-regulated ABA, as well as any product which results, directly or indirectly, from combination of ABA with specified ingredients in the specified amounts.
  • The term “effective amount” means an amount of a compound that, when administered to livestock or fish for treating a disease, condition or attaining a desired result, is sufficient to effect such treatment for the disease or desired result. The “effective amount” will vary depending on the compound, the disease state being treated or health benefit desired, the severity or the disease treated, the result desired, the age and relative health of the livestock or fish, the route and form of administration, the judgment of the attending medical or veterinary practitioner, breeder, trainer, or person attending or caring for the livestock or fish, and other factors. The amount of ABA that is “effective” will vary from composition to composition, depending on the particular use, the particular ABA, salts, derivatives and analogs thereof, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective amount” in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
  • The term “Metric Ton” (MT) refers to 2,205 pounds or 1,000 kg. The term “ton”, also known as a “short ton”, refers to 2,000 pounds or 907 kg.
  • As used herein, all numerical values relating to amounts, weight percentages and the like are defined as “about” or “approximately” each particular value, namely, plus or minus 10%. For example, the phrase “at least 5% by weight” is to be understood as “at least 4.5% to 5.5% by weight.” Therefore, amounts within 10% of the claimed values are encompassed by the scope of the claims.
  • Composition Form for Administration
  • The compositions of the present invention may be incorporated with compound feed, or commercial pelleted food produced in a feed mill and fed to domestic livestock and fish. In varying embodiments, the compositions of the present invention may be incorporated with fodder, or food given to domestic livestock including plants cut and carried to them. In other varying embodiments, the compositions of the present invention may be incorporated with forage, or growing plants eaten by domestic livestock. It is within a skill in the art to formulate the compositions with foodstuffs for oral consumption.
  • In a different embodiment, the compositions of the present invention may be formulated in a liquid composition for oral consumption. It is within a skill in the art to formulate the compositions in liquid compositions for oral consumption.
  • In yet another embodiment, the compositions of the present invention may be added to water used for livestock or fish production. In yet another varying embodiment, the composition of the present invention is added to an aquaculture system used to grow fish, aquatic mammals, or crustaceans.
  • Diseases and Conditions to be Treated with Compositions and Methods of the Invention
  • An embodiment of the present invention is directed to methods of reducing mortality of livestock and fish comprising administering to livestock or fish an effective amount of ABA.
  • Another varying embodiment of the present invention is directed to methods of increasing weight gain of livestock and fish comprising administering to livestock and fish an effective amount of ABA.
  • It is contemplated that another embodiment of the present invention is directed to methods of decreasing the time to market of livestock and fish comprising administering to livestock and fish an effective amount of ABA. It is also contemplated that a different embodiment of the present invention is directed to methods of increasing the meat quantity of livestock and fish comprising administering to livestock and fish an effective amount of ABA.
  • An embodiment of the present invention is directed to methods of increasing immunological function in livestock and fish comprising administering to livestock or fish in need thereof an effective amount of ABA.
  • A preferred range of an effective amount of ABA for the various methods is from about 1 gram/MT of feed to about 2000 grams/MT of feed. A more preferred range of ABA is from about 5 grams/MT of feed to about 500 grams/MT of feed. A person having ordinary skill in the art would be able to adjust these ranges for various uses like aquaculture applications without undue experimentation.
  • Animal Feed
  • Animal feed for feeding poultry includes protein, fat, fiber, calcium, and phosphorous. A preferred feed would include corn and/or wheat, soybean meal, fat, animal by-product, meat and bone meal, and vitamins and minerals.
  • When used in poultry feed, ABA can be initially mixed into a premix. The term “premix” is intended to mean a feed composition that is prepared as an initial mix containing the active ingredient and, for example, a carrier, and is then blended into the final feed. In the present invention, it is generally suggested that, for ease of calculation and use, the premix is blended with about one metric ton (MT) of conventional feed, with the result that the necessary dosage requirements of the ABA are provided to the animals. When preparing one metric ton (MT) of finished feed, the premix of the invention preferably comprises about 1 to 2000, and more preferably, about 5 to 500, grams of ABA. Carriers for use in a premix are well known by those having skill in the art, and appropriate concentrations can be readily determined.
  • The ABA may be added to the carrier as a dry powder or as a liquid solution or suspension. When added as a liquid, the ABA may be dissolved or suspended in a liquid with stirring at room temperature. Such liquid may be water or a suitable solvent or another product used for animal feed that is already in liquid form. Because of ABA's liquid solubility characteristics, it may form a suspension. A predetermined amount of ABA is then added to the conventional premix, and will not overly wet it. Once the premix is prepared, the premix is then added to the final feed, preferably at a rate in the range of one quarter of a pound (lb.) to five pounds (lbs.) of premix to one metric ton (MT) of feed, to supply daily requirements of the ABA for the poultry.
  • The ABA solid or solution or liquid suspension can be added directly to the premix material, and then mixed. Mixing can be accomplished by any known means, such as by a standard horizontal or vertical blender. Mixing time will again vary depending upon the particular ingredients of the premix, and can take as long as is necessary to assure that the ingredients are thoroughly mixed.
  • The premix is then incorporated into the feed to be fed to the poultry. In a more preferred embodiment, ABA is blended with the carrier to form the premix, and the premix is directly blended into the final feed. While there is no evidence that use of the higher amounts would cause any toxicity problems in treated poultry, it will affect cost considerations. Because the premix generally will be added to one-ton charges of feed (as is common in the industry), the correspondence between one gram of ABA added to the premix yields about 1 ppm concentration of ABA in the feed. Thus, 5 grams of ABA added to one pound of premix, which in turn is added to one metric ton (MT) of feed, yields about a 5 ppm effective ABA concentration.
  • While the ABA can be mixed with a premix material prior to incorporation into the finished feed, the appropriate amount of ABA may be directly blended into or sprayed upon the feed. The preferred additive range of ABA in finished feed, whether added directly or via a premix, is about 1 to 2000 grams per metric ton (MT) of feed; more preferably about 5 to 500 grams per metric ton (MT) of feed.
  • Feed is conventionally prepared in a large bin or mixer in which the feed ingredients are added in descending weight order according to their prevalence in the ultimate feed mixture. Thus, cracked or ground grain would be the primary ingredient. Minor ingredients are then added. Micro-ingredients are added last. These include vitamins, drugs, growth promoters, antibiotics, and, in the present case, ABA. Thus, ABA can be one of the micro-ingredients and is added to the feed in the final blending step. The feed is blended for conventional time periods.
  • The feed comprising the ABA is fed to livestock and fish in standard form, such as a mash, crumble or pellet, and at standard feed dosage ranges and rates.
  • Another embodiment of the present invention is liquid compositions that can be prepared as either ready-to-use dilutions or dilutable concentrates. The embodiment of the present invention can be a solution containing from 0.5% to as much as 50% by weight of ABA. The dilutable concentrates can be diluted into water directly to a final application concentration or to any intermediate dilution, without risk of precipitation of the active ingredient. The aqueous formulations according to one embodiment of the present invention are inexpensive to manufacture, safe to handle and use, and the ABA active ingredient is stable under storage and shipping conditions. A person having ordinary skill in the art would be able to determine how to prepare the final aqueous solution concentration for direct application to animals without undue experimentation, without any chance of causing precipitation of the active ingredient, and without long and laborious stirring to bring the active ingredient into solution.
  • Another embodiment of the present invention is an ABA water solution that serves as a drinking source of water for the livestock and fish. Such supplemented water solution could be prepared by dissolving dry powder ABA in drinking water or by using a liquid solution or suspension concentrate of ABA. The preferred additive range of ABA in drinking water is about 1 to 2000 parts per million (ppm) or about 1 to 2000 milligrams of ABA per liter of water; more preferably about 5 to 500 parts per million (ppm) or about 5 to 500 milligrams of ABA per liter of water. A person having ordinary skill in the art would be able to determine how to prepare the final aqueous solution for direct application to livestock and fish without undue experimentation, without any chance of causing precipitation of the active ingredient, and without long and laborious stirring to bring the active ingredient into solution.
  • In another embodiment of the present invention ABA can be applied directly onto animal feed once it has been prepared. For example, as can be the practice with some enzymes, the ABA can be applied directly to the finished feed. In a preferred embodiment, an aqueous solution of ABA is sprayed onto the finished feed in its final form, such as a pellet, prior to delivering the feed to the livestock and fish.
  • The advantageous properties of this invention can be observed by reference to the following examples that illustrate the invention. These examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention.
  • The following examples are intended to illustrate the present invention and to teach one of ordinary skill in the art how to make and use the invention. They are not intended to limit the invention or its protection in any way.
  • Example 1
  • Male Cobb 500 chickens were fed different levels of S-ABA supplemented into starter, grower, and finisher feed diets for their entire 42 day commercial life cycle. On day 43, samples of chickens (sometimes referred to as “birds”) from each treatment were processed.
  • A. Basal and Experimental Diets
  • The starter, grower, and finisher basal diets represented standard commerical broiler diets. The starter and grower diets contained Salinomycin (a coccidiostat) at 40 grams/ton. The basal diets and final treatment diets were prepared using a 500 or 4,000 pound capacity vertical mixer or a 14,000 pound capacity horizontal mixer. After correcting for percent purity of S-ABA in the S-ABA dry powder, S-ABA was added to the basal diets at concentrations of 5, 50, or 500 ppm (4.6, 46, or 455 grams of S-ABA/ton). Control treatments included (1) commercial diet only and (2) commercial diet supplemented with antibiotics (bacitracin methylene disalicylate (BMD), and STAFAC® virginiamycin (hereinafter “Stafac”). STAFAC is a registered trademark of Phibro Animal Health Corporation). All feed diets were pelleted at ˜65° C. or below.
  • B. Test Groups
  • A 90-pen test facility was divided into 10 blocks containing 9 pens per block. Treatments were assigned to the pens using a complete randomized block design. Birds were assigned to the pens randomly. Specific treatment groups were as follows:
  • No. of No. of No. of ~Feed
    Diet Birds per Pens per Birds per Consumption
    Treatment Diet Code Litter Pen* Treatment Treatment (kg)
    1 Commercial A Clean 18 10 180 1,209
    feed diet
    2 S-ABA 5 ppm B Clean 18 10 180 1,209
    3 S-ABA 50 ppm C Clean 18 10 180 1,209
    4 S-ABA 500 ppm D Clean 18 10 180 1,209
    5 Commercial A Dirty 18 10 180 1,209
    feed diet
    6 S-ABA 5 ppm B Dirty 18 10 180 1,209
    7 S-ABA 50 ppm C Dirty 18 10 180 1,209
    8 S-ABA 500 ppm D Dirty 18 10 180 1,209
    9 BMD 50 grams/ton in starter E Dirty 18 10 180 1,209
    feed diet, 25 grams/ton in
    grower feed diet,
    Stafac 10 grams/ton in
    finisher feed diet
    Total 90 1,620 10,881
    *Two (2) extra chicks were placed in each pen on day 0 (20 birds/pen). At 7 days of age the birds in each pen were counted and bird counts in each pen were adjusted to 18 birds/pen. Extras were weighed, recorded, and removed.
  • C. Management Vaccinations and Treatments:
  • Birds were vaccinated for Mareks at the hatchery. Birds were vaccinated upon receipt for the study (day 0) for Newcastle and Infectious Bronchitis via spray cabinet. No other vaccinations or treatments, except what is provided in the diets were administered during the study.
  • Water:
  • Water was provided ad libitum throughout the study via one automatic four-nipple drinker in each pen. Drinkers were checked twice daily to assure a constant and clean water supply to the birds.
  • Feed:
  • Feed was provided ad libitum throughout the study via one handing, ˜17-inch diameter tube feeder per pen. Chick feeder trays were placed in each pen for approximately the first 4 days. Feed added and removed from pens was weighed and recorded from day 0 to day 42. Diet changes were conducted at the same time for all pens. The feeding period for each diet was as shown below:
  • Diet Form Feeding Period (Days)
    Starter Crumble  0-14
    Grower Pellet 14-28
    Finisher Pellet 28-42
  • Mortality:
  • Starting on study day 0, any bird found dead or needing to be removed and sacrificed was weighed and necropsied. The probable cause of death and necropsy findings were recorded.
  • Body Weights and Feed Intake:
  • Birds were weighed by pen at 0, 7, 14, 21, 28, 35, and 42 days of age. The feed remaining in each pen was weighed and recorded on study day 0, 7, 14, 21, 28, 35, and 42 days of age. The feed intake during days 0-7, 0-14, 0-21, 0-28, 0-35, and 0-42 was calculated.
  • Weight Gains and Feed Conversion:
  • Performance data was summarized by average weight per bird at each body weights measurement period. The average feed conversion was calculated for each respective body weight period using the total feed consumption in a pen divided by the total weight of surviving birds (i.e. days 0-7, 0-14, 0-21, etc.). Adjusted feed conversion was calculated using the total feed consumption in a pen divided by the total weight of surviving birds and weight of birds that died or were removed from that pen.
  • Processing:
  • Four blocks (9 pens/block) were selected at random from each treatment. On day 42 all birds in the selected blocks were individually wing banded with a unique number. Prior to processing the birds were fasted for approximately 12 hours. Immediately after processing on day 43, digestive tract weights and Bursa of Fabricius organ weights were measured.
  • D. Results
  • TABLE 1 shows that 5 ppm S-ABA added to commercial feed diets had significantly (P=0.05) lower bird mortality compared to the control treatments, including the commercial feed diet containing the bacitracin methylene disalicylate and Stafac antibiotics.
  • TABLE 1
    Cumulative Bird Mortality After 42 Days
    Treatment* Lived Died
    Commercial feed diet (control 1) 194 6
    Commercial feed diet plus BMD, Stafac (control 2) 194 6
    Commercial feed diet plus 5 ppm S-ABA 200 0
    *Dirty litter conditions
  • The greater level of bird health in response to S-ABA, as shown in TABLE 1 above, was observed under dirty litter conditions, which represents a challenging and stressful living environment for the birds.
  • TABLE 2 shows that 5 ppm S-ABA added to commercial feed increased bird growth (weights) compared to the commercial feed diet (control 1). The addition of 5 ppm S-ABA to the commercial feed diet also reduced feed conversion ratios by 1-4 points. Feed conversion ratios that were corrected for the number of surviving birds (i.e., adjusted feed conversion ratios) were lower by 1-2 points.
  • TABLE 2
    Bird Weights and Feed Conversion Ratios*
    Means Means Means Means Means Means
    Day 7 Day 14 Day 21 Day 28 Day 35 Day 42
    Bird Weight (kg)
    Commercial feed diet 0.1427 0.3763 0.7588 1.3785 2.0704 2.7010
    (control 1)
    versus vs. vs. vs. vs. vs. vs.
    Commercial feed diet 0.1445 0.3873 0.7899 1.4236 2.0919 2.7565
    plus 5 ppm S-ABA
    Feed/Gain Ratio
    Commercial feed diet 1.4505 1.3544 1.4245 1.4915 1.5864 1.6818
    (control 1)
    versus vs. vs. vs. vs. vs. vs.
    Commercial feed diet 1.4093 1.3400 1.4137 1.4584 1.5731 1.6861
    plus 5 ppm S-ABA
    Adjusted Feed/Gain
    Ratio
    Commercial feed diet 1.4218 1.3009 1.4028 1.4617 1.5652 1.6649
    (control 1)
    versus vs. vs. vs. vs. vs. vs.
    Commercial feed diet 1.4093 1.2854 1.3842 1.4517 1.5610 1.6691
    plus 5 ppm S-ABA
    *Dirty litter conditions
  • Increased bird growth, as evidenced by the greater weights shown in TABLE 2, suggests that the addition of S-ABA to commercial feed can lead to faster growth and bigger birds. This response to S-ABA could prove useful by reducing the number of days to reach a given target bird size (weight). The reduction in feed conversion ratios means the addition of S-ABA to animal feed can lower the cost to produce a given unit of meat (e.g., a pound of chicken breast meat).
  • TABLE 3 shows that S-ABA in the feed diet increases the weight of digestive tracts compared to the commercial feed diets (control 1 and control 2).
  • TABLE 3
    Digestive Tract Weights
    Mean Weight
    Treatment* (Grams)
    Commercial feed diet plus 500 ppm S-ABA 88.4
    Commercial feed diet plus 5 ppm S-ABA 86.7
    Commercial feed diet plus 50 ppm S-ABA 86.6
    Commercial feed diet plus BMD, Stafac 85.9
    (control 2)
    Commercial feed diet 84.4
    (control 1)
    *Dirty litter conditions
  • Increased digestive tract weights, as shown in TABLE 3 above, may be directly related to better overall health. Further, data in TABLE 3 suggest that S-ABA may also reduce or eliminate the need for antibiotics in feed.
  • With these data (TABLES 1-3), one can see that S-ABA improves the health and growth of chickens and increases feed efficiencies so that producers can save costs.
  • TABLE 4 shows the economic benefit of improved health and growth of broiler chickens and increased feeding efficiency resulting from the addition of S-ABA into commercial feed.
  • TABLE 4
    Profit Value per 1,000 Birds Started*
    Commercial feed diet plus
    Commercial feed diet BMD, Stafac
    (control 1) (control 2)
    versus versus
    Base Feed Cost Commercial feed diet Commercial feed diet plus 5
    ($/ton) plus 5 ppm S-ABA ppm S-ABA
    $150 $112.75 $68.74
    $200 $99.44 $61.74
    $250 $86.12 $54.73
    $325 $66.16 $44.22
    *See U.S. Pat. No. 5,715,185; also Poultry USA magazine, May 2003, pgs 34-40.
  • The tabulated results in TABLE 4 show that by decreasing broiler chicken production costs through better health increased bird growth, and improved feed conversion efficiencies, the addition of ABA into commercial broiler feed can result in meaningful economic benefit to the industry. For instance, at a base feed cost of $250/ton when compared to the commercial feed diet (control 1), the addition of 5 ppm S-ABA to the diet added an incremental $86.12 in profit value per 1,000 birds started. Compared to the commercial feed diet plus BMD and Stafac (control 2), the addition of 5 ppm S-ABA to the diet increased the profit value per 1,000 birds started by $54.73.
  • Example 2
  • Male and female Cobb 500 chickens were fed different levels of (s)-(+)-abscisic acid (S-ABA) supplemented into starter, grower, and finisher feed diets for their entire 42 days commercial life cycle.
  • A. Basal and Experimental Diets
  • The starter, grower, and finisher basal diets represented standard commercial broiler diets. The starter and grower diets contained Salinomycin (a coccidiostat) at 40 grams/ton. The basal diets and final treatment diets were prepared using a 500 or 4,000 pound capacity vertical mixer or a 14,000 pound capacity horizontal mixer. After correcting for percent purity of S-ABA in the S-ABA dry powder, S-ABA was added to the basal diets at concentrations of 2.5, 5.0, or 7.5 ppm (2.3, 4.6, or 6.8 grams of S-ABA/ton). Control treatments included (1) commercial diet only and (2) commercial diet supplemented with antibiotics (bacitracin methylene disalicylate and Stafac). All feed diets were pelleted at ˜65° C. or below.
  • B. Test Groups
  • A 108-pen test facility was divided into 18 blocks containing 6 pens per block. Treatments were assigned to the pens using a complete randomized block design. Birds were assigned to the pens randomly. Specific treatment groups were as follows:
  • No. of No. of No. of
    Diet Birds per Pens per Birds per
    Treatment Diet Code Sex Pen* Treatment Treatment
    1 Commercial A F 18 18 324
    feed diet
    2 BMD 50 grams/ton in starter B F 18 18 324
    feed diet, 25 grams/ton in
    grower feed diet,
    Stafac 10 grams/ton in
    finisher
    3 S-ABA 2.5 ppm C F 18 18 324
    4 S-ABA 5.0 ppm D F 18 18 324
    5 S-ABA 7.5 ppm E F 18 18 324
    6 S-ABA 5.0 ppm D F 18 18 324
    7 Commercial A M 18 18 324
    feed diet
    8 BMD 50 grams/ton in starter B M 18 18 324
    feed diet, 25 grams/ton in
    grower feed diet,
    Stafac 10 grams/ton in
    finisher
    9 S-ABA 2.5 ppm C M 18 18 324
    10 S-ABA 5.0 ppm D M 18 18 324
    11 S-ABA 7.5 ppm E M 18 18 324
    12 S-ABA 5.0 ppm D M 18 18 324
    Total 216 3,888
    *Nine (9) extra chicks were placed in each pen on day 0 (27 birds/pen). At 21 days of age, after pen weights, the birds were counted and adjusted by randomly selecting and removing the appropriate number of birds to achieve 18 birds/pen. Composite weights were taken on the removed birds and then subtracted from the initial 21 day weights.
  • C. Management Vaccinations and Treatments:
  • Birds were vaccinated for Mareks at the hatchery. Birds were vaccinated upon receipt for the study (day 0) for Newcastle and Infectious Bronchitis via spray cabinet. No other vaccinations or treatments, except what is provided in the diets were administered during the study.
  • Water:
  • Water was provided ad libitum throughout the study via one automatic four-nipple drinker in each pen. Drinkers were checked twice daily to assure a constant and clean water supply to the birds.
  • Feed:
  • Feed was provided ad libitum throughout the study via one handing, ˜17-inch diameter tube feeder per pen. Chick feeder trays were placed in each pen for approximately the first 4 days. Feed added and removed from pens was weighed and recorded from day 0 to day 42. Diet changes were conducted at the same time for all pens. The feeding period for each diet was as shown below:
  • Diet Form Feeding Period (Days)
    Starter Crumble  0-21
    Grower Pellet 21-35
    Finisher Pellet 35-42
  • Mortality:
  • Starting on study day 0, any bird found dead or needing to be removed and sacrificed was weighed and necropsied. The probable cause of death and necropsy findings were recorded.
  • Body Weights and Feed Intake:
  • Birds were weighed by pen at 0, 7, 14, 21, 28, 35, and 42 days of age. The feed remaining in each pen was weighed and recorded on study day 0, 7, 14, 21, 28, 35, and 42 days of age. The feed intake during days 0-7, 0-14, 0-21, 0-28, 0-35, and 0-42 was calculated.
  • Weight Gains and Feed Conversion:
  • Performance data was summarized by average weight per bird at each body weights measurement period. The average feed conversion was calculated for each respective body weight period using the total feed consumption in a pen divided by the total weight of surviving birds (i.e. days 0-7, 0-14, 0-21, etc.). Adjusted feed conversion was calculated using the total feed consumption in a pen divided by the total weight of surviving birds and weight of birds that died or were removed from that pen.
  • D. Results
  • TABLE 5 shows that ABA added to commercial feed diets had higher survival rates compared to the commercial feed diet containing the bacitracin methylene disalicylate and Stafac antibiotics.
  • TABLE 5
    Cumulative Bird Mortality After 42 Days
    Treatment* Sex Mortality
    Commercial feed diet Female 1.8%
    BMD 50 grams/ton in starter feed diet, 25 Female 3.5%
    grams/ton in grower feed diet,
    Stafac 10 grams/ton in finisher
    S-ABA 2.5 ppm Female 2.4%
    S-ABA 5.0 ppm Female 0.4%
    S-ABA 7.5 ppm Female 2.2%
    S-ABA 5.0 ppm Female 1.9%
    Commercial feed diet Male 3.0%
    BMD 50 grams/ton in starter feed diet, 25 Male 4.5%
    grams/ton in grower feed diet,
    Stafac 10 grams/ton in finisher
    S-ABA 2.5 ppm Male 4.1%
    S-ABA 5.0 ppm Male 2.9%
    S-ABA 7.5 ppm Male 3.8%
    S-ABA 5.0 ppm Male 3.5%
    *Dirty litter conditions
  • The greater level of bird survival in the S-ABA treatments, as shown in TABLE 5 above, was observed under dirty litter conditions, which represents a more challenging and stressful living environment for the birds. This suggests that additional S-ABA in the feed may help improve bird health.
  • With these results (TABLES 1-5), one can see that S-ABA improves the health and growth of chickens and increases feeding efficiency so that producers can save costs. Taking these various parameters into consideration, the benefits of supplementing animal feed with additional S-ABA means greater economic benefit to animal producers by improving operating efficiencies during bird production and higher meat yield upon processing.

Claims (7)

1. A method maintaining the health of livestock or fish comprising administering to livestock or fish in need thereof an effective amount of abscisic acid, and/or salts, and derivatives thereof.
2. A method of increasing feed efficiency comprising administering to livestock or fish an effective amount of abscisic acid, and/or salts, and derivatives thereof.
3. A method of increasing weight gain of livestock or fish, comprising administering to livestock or fish an effective amount of abscisic acid, and/or salts, and derivatives thereof.
4. A method of decreasing the time to market of livestock or fish, comprising administering to livestock or fish an effective amount of abscisic acid, and/or salts, and derivatives thereof.
5. A method of increasing the meat quantity of livestock or fish, comprising administering to livestock or fish an effective amount of abscisic acid, and/or salts, and derivatives thereof.
6. A feed composition for administration to livestock or fish comprising abscisic acid, and/or salts, and derivatives thereof.
7. A method for reducing or eliminating the use of antibiotics in feed comprising administering to livestock or fish an effective amount of abscisic acid, and/or salts, and derivatives thereof.
US13/236,472 2010-09-17 2011-09-19 Animal feed compositions of abscisic acid Abandoned US20120071557A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/236,472 US20120071557A1 (en) 2010-09-17 2011-09-19 Animal feed compositions of abscisic acid
US14/717,110 US20150250209A1 (en) 2010-09-17 2015-05-20 Animal feed compositions of abscisic acid
US16/593,677 US20200030269A1 (en) 2010-09-17 2019-10-04 Animal feed compositions of abscisic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38402010P 2010-09-17 2010-09-17
US13/236,472 US20120071557A1 (en) 2010-09-17 2011-09-19 Animal feed compositions of abscisic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/717,110 Division US20150250209A1 (en) 2010-09-17 2015-05-20 Animal feed compositions of abscisic acid

Publications (1)

Publication Number Publication Date
US20120071557A1 true US20120071557A1 (en) 2012-03-22

Family

ID=45818303

Family Applications (9)

Application Number Title Priority Date Filing Date
US13/236,444 Abandoned US20120071555A1 (en) 2010-09-17 2011-09-19 Compositions of abscisic acid for animal health
US13/236,472 Abandoned US20120071557A1 (en) 2010-09-17 2011-09-19 Animal feed compositions of abscisic acid
US13/236,462 Active 2032-02-06 US8536224B2 (en) 2010-09-17 2011-09-19 Pharmaceutical and nutraceutical compositions of abscisic acid
US14/014,665 Active US8729122B2 (en) 2010-09-17 2013-08-30 Pharmaceutical and nutraceutical compositions of abscisic acid
US14/463,987 Active US9591867B2 (en) 2010-09-17 2014-08-20 Compositions of abscisic acid for animal health
US14/717,110 Abandoned US20150250209A1 (en) 2010-09-17 2015-05-20 Animal feed compositions of abscisic acid
US15/423,068 Ceased US10238613B2 (en) 2010-09-17 2017-02-02 Compositions of abscisic acid for animal health
US16/541,385 Active USRE48854E1 (en) 2010-09-17 2019-08-15 Compositions of abscisic acid for animal health
US17/495,128 Abandoned US20220023243A1 (en) 2010-09-17 2021-10-06 Compositions of abscisic acid for animal health

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/236,444 Abandoned US20120071555A1 (en) 2010-09-17 2011-09-19 Compositions of abscisic acid for animal health

Family Applications After (7)

Application Number Title Priority Date Filing Date
US13/236,462 Active 2032-02-06 US8536224B2 (en) 2010-09-17 2011-09-19 Pharmaceutical and nutraceutical compositions of abscisic acid
US14/014,665 Active US8729122B2 (en) 2010-09-17 2013-08-30 Pharmaceutical and nutraceutical compositions of abscisic acid
US14/463,987 Active US9591867B2 (en) 2010-09-17 2014-08-20 Compositions of abscisic acid for animal health
US14/717,110 Abandoned US20150250209A1 (en) 2010-09-17 2015-05-20 Animal feed compositions of abscisic acid
US15/423,068 Ceased US10238613B2 (en) 2010-09-17 2017-02-02 Compositions of abscisic acid for animal health
US16/541,385 Active USRE48854E1 (en) 2010-09-17 2019-08-15 Compositions of abscisic acid for animal health
US17/495,128 Abandoned US20220023243A1 (en) 2010-09-17 2021-10-06 Compositions of abscisic acid for animal health

Country Status (10)

Country Link
US (9) US20120071555A1 (en)
EP (5) EP2616059B1 (en)
JP (8) JP5898206B2 (en)
CN (6) CN103179963B (en)
BR (2) BR112013005912B1 (en)
CA (2) CA2809641C (en)
DK (1) DK2616059T3 (en)
ES (2) ES2545866T3 (en)
MX (7) MX2013002947A (en)
WO (3) WO2012037562A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037562A2 (en) * 2010-09-17 2012-03-22 Valent Biosciences Corporation Pharmaceutical and nutraceutical compositions of abscisic acid
WO2015106050A1 (en) 2014-01-10 2015-07-16 Valent Biosciences Corporation (s)-3'-methyl-abscisic acid and esters thereof
CA2952186C (en) 2014-07-08 2022-08-23 Valent Biosciences Corporation 3'-substituted-abscisic acid derivatives
US20180183541A9 (en) 2014-07-17 2018-06-28 NUTRAVIS S.r.l. A New Treatment For Improving The Use Of Dietary Sugar For Energy Purposes
CA3200879A1 (en) 2020-12-16 2022-06-23 Tsuyoshi TONOUE Abscisic acid-mixed pig feed
EP4265121A1 (en) * 2020-12-16 2023-10-25 Sumitomo Chemical Company, Limited Livestock feed
US20240049752A1 (en) 2021-02-17 2024-02-15 Sumitomo Chemical Company, Limited Livestock Feed
KR20230143615A (en) 2021-02-17 2023-10-12 스미또모 가가꾸 가부시키가이샤 feed for livestock
TW202301989A (en) 2021-02-17 2023-01-16 日商住友化學股份有限公司 Feed for livestock
TW202304315A (en) 2021-04-07 2023-02-01 日商住友化學股份有限公司 Feed for livestock
US20220369630A1 (en) * 2021-05-06 2022-11-24 Stoller Enterprises, Inc. Stable S-(+)-Abscisic Acid Nonaqueous Liquid Solutions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3958025A (en) * 1972-10-06 1976-05-18 Livingston Virginia W C Abscisic acid tablets and process

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1182508A (en) 1914-09-05 1916-05-09 Underwood Typewriter Co Automatic type-writer operator.
US1184608A (en) 1915-06-07 1916-05-23 Berger Specialty Mfg Company Inc Bottle-holder.
US4209530A (en) 1978-07-28 1980-06-24 Endowment And Research Foundation At Montana State University Insect control compositions employing abscisic acid
US4434180A (en) 1978-07-28 1984-02-28 Visscher Saralee N Insect control methods with abscisic acid
US5834473A (en) * 1993-04-29 1998-11-10 Cultor, Ltd. Method for treating coccidiosis
CA2170142C (en) * 1993-08-27 2010-05-25 Jose M. Wade Composition and method for stimulation of reproductive performance
JP2001181632A (en) * 1999-10-14 2001-07-03 Nisshin Oil Mills Ltd:The Antioxidant
IT1320180B1 (en) * 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme NUTRITIONAL AND THERAPEUTIC PREPARATIONS EQUIPPED WITH ANTI-OXIDANT ACTIVITY AND ABLE TO CONTROL THE PONDERAL EXCESSES AND
US7718699B1 (en) 2005-03-04 2010-05-18 Broyles Robert H Abscissic acid and derivatives thereof for the treatment of diseases
CN100426996C (en) * 2004-08-02 2008-10-22 阳麈苇 Anticancer healthy drink of abscisic acid
CN1748674A (en) * 2004-09-14 2006-03-22 中国科学院成都生物研究所 Natural abscisic acid is used to prepare the new purposes of tumor cell " differentiating inducer " medicine
JP2006232807A (en) * 2005-01-27 2006-09-07 Toyobo Co Ltd Antioxidant containing horseradish extract
CN1686174A (en) * 2005-04-18 2005-10-26 杨奇彪 Tumour inhibitor formula for preventing and treating malignant tumour
EP1714674A1 (en) * 2005-04-21 2006-10-25 Desol BV Method for improving the fertility of animals
EP1714673A1 (en) * 2005-04-21 2006-10-25 Desol BV Method for lengthening the mobility period of fish
US8389024B2 (en) * 2005-06-22 2013-03-05 Gonzalo Romero M. Abscisic acid against cancer
US20060292215A1 (en) 2005-06-22 2006-12-28 Gonzalo Romero M Abscisic acid against cancer
ITTO20050708A1 (en) 2005-10-07 2007-04-08 Univ Degli Studi Genova FLURIDONE AS AN ANTI-INFLAMMATORY AGENT
US7741367B2 (en) * 2006-02-08 2010-06-22 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
US8367727B2 (en) * 2006-02-08 2013-02-05 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
JP2008074725A (en) * 2006-09-19 2008-04-03 Noevir Co Ltd Humectant, arginase activity promoter, cell activator, collagen production promoter, hyaluronic acid production promoter, antioxidant and neutral fat accumulation inhibitor
JP2009000045A (en) * 2007-06-21 2009-01-08 Unitika Ltd Feed mixing agent
JP5268086B2 (en) * 2007-10-02 2013-08-21 国立大学法人岩手大学 Cordyceps culture method and immunostimulant, cancer cell growth inhibitor, anti-inflammatory agent, or antioxidant containing Cordyceps as an active ingredient
US8320308B2 (en) 2007-11-07 2012-11-27 Stmicroelectronics, Inc. Parallel data services and spectrum sensing with cognitive channel switching in a wireless area network
US9063122B2 (en) * 2008-10-17 2015-06-23 Alfredo Gallegos Biomodulators for treatment or prevention of disease
JP5451281B2 (en) 2009-09-16 2014-03-26 ピーエスフォー ルクスコ エスエイアールエル Sense amplifier circuit and semiconductor device including the same
WO2011150160A2 (en) * 2010-05-26 2011-12-01 Virginia Tech Intellectual Properties, Inc. Method of preventing and treating inflammatory diseases and disorders with abscisic acid
WO2012037562A2 (en) * 2010-09-17 2012-03-22 Valent Biosciences Corporation Pharmaceutical and nutraceutical compositions of abscisic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3958025A (en) * 1972-10-06 1976-05-18 Livingston Virginia W C Abscisic acid tablets and process

Also Published As

Publication number Publication date
MX2013002949A (en) 2013-05-09
JP2013542925A (en) 2013-11-28
CN103179963A (en) 2013-06-26
CN103179964B (en) 2015-12-02
US20170143651A1 (en) 2017-05-25
EP3228311A3 (en) 2018-01-10
JP2019163315A (en) 2019-09-26
CN103179965A (en) 2013-06-26
EP3228311A2 (en) 2017-10-11
ES2545867T9 (en) 2017-02-17
MX340983B (en) 2016-08-01
US20140364501A1 (en) 2014-12-11
US9591867B2 (en) 2017-03-14
CA2809641A1 (en) 2012-03-22
JP7217763B2 (en) 2023-02-03
US8536224B2 (en) 2013-09-17
EP2616060B1 (en) 2015-08-12
JP2017222688A (en) 2017-12-21
JP2021075557A (en) 2021-05-20
US20220023243A1 (en) 2022-01-27
US10238613B2 (en) 2019-03-26
BR112013005915A2 (en) 2016-05-17
JP2020019782A (en) 2020-02-06
BR112013005912B1 (en) 2021-07-13
DK2616059T3 (en) 2017-10-23
CA3047772C (en) 2021-07-20
US20130345308A1 (en) 2013-12-26
JP6602440B2 (en) 2019-11-06
EP2616058B1 (en) 2015-08-12
BR112013005912A2 (en) 2016-05-17
US8729122B2 (en) 2014-05-20
ES2545866T3 (en) 2015-09-16
USRE48854E1 (en) 2021-12-21
EP2616059A4 (en) 2014-03-26
CN105640929A (en) 2016-06-08
BR112013005914A2 (en) 2016-05-17
MX2013002947A (en) 2013-05-09
US20120071555A1 (en) 2012-03-22
WO2012037562A3 (en) 2012-08-02
CN103179964A (en) 2013-06-26
BR112013005914B1 (en) 2020-10-06
JP5898206B2 (en) 2016-04-06
EP2616058A4 (en) 2013-10-09
CA3047772A1 (en) 2012-03-22
WO2012037562A2 (en) 2012-03-22
CN105878224A (en) 2016-08-24
EP2616059A2 (en) 2013-07-24
CN111494353A (en) 2020-08-07
MX340751B (en) 2016-07-22
JP2019031557A (en) 2019-02-28
US20120071556A1 (en) 2012-03-22
MX340147B (en) 2016-06-28
EP2616059B1 (en) 2017-07-05
EP2616060A1 (en) 2013-07-24
WO2012037561A1 (en) 2012-03-22
MX340752B (en) 2016-07-22
CA2809641C (en) 2019-09-10
EP2616058A1 (en) 2013-07-24
EP3598970A1 (en) 2020-01-29
MX2013002948A (en) 2013-05-09
WO2012037563A1 (en) 2012-03-22
EP2616060A4 (en) 2013-10-09
US20150250209A1 (en) 2015-09-10
JP2016166188A (en) 2016-09-15
ES2545867T3 (en) 2015-09-16
CN103179963B (en) 2016-07-06
JP2023012490A (en) 2023-01-25

Similar Documents

Publication Publication Date Title
EP2616058B1 (en) Animal feed compositions of abscisic acid
US20200030269A1 (en) Animal feed compositions of abscisic acid
KR101889859B1 (en) Animal feed additive having an antimicrobial and growth-promoting effect
KR102112351B1 (en) Treatment of poultry, pigs or fish for reducing the feed conversion ratio or increasing their bodyweight gain
RU2485793C2 (en) "verva" biologically active fodder additive
CN108029863B (en) Application of butyrylglycine and derivative thereof in preparation of animal feed additive
WO2022253361A1 (en) Use of furan formic acid compound in preparing animal feed additive
HU187467B (en) Method for producing preparation suitable for preventing health deterioration of alimentary origin promoting the utilization of fodder of animals
RU2580358C1 (en) Method of increasing productivity of farm birds
RU2635695C2 (en) Method of increasing growth of broiler chickens
US4666891A (en) Method of stimulating animal growth by administering feed and inosine complex
US20030170342A1 (en) Choline acids as feed additive in animal nutrition
WO2017143665A1 (en) Compound feeding composition and application thereof in preparation of animal feed additive
JP2000053565A (en) Prevention and improvememnt in production disease of genetically improved domestic animal and domestic fowl
JPS5877812A (en) Method and composition for increasing reproduction of mammels or birds
US3719758A (en) Method of promoting growth and improving feed efficiency in poultry and swine via oral administration of cephalosporin c
JP3133550B2 (en) Animal growth promoting composition
JPH06327412A (en) Growth-promoting or improving feed and method
WO2017143668A1 (en) Applications of myristic acid derivative in preparing animal growth promoter
JPH08245396A (en) Agent for anticholesterol
BG100673A (en) Application of balchemicine for increasing animal productivity and compositions increasing the productivity

Legal Events

Date Code Title Description
AS Assignment

Owner name: VALENT BIOSCIENCES CORPORATION, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HERRERO, MARIA PILAR;SHAFER, WARREN E.;REEL/FRAME:027254/0285

Effective date: 20111007

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION